Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc (DE:6C1)
FRANKFURT:6C1
RESEARCH TOOLSreports
CytomX Therapeutics (6C1) Stock Price & Analysis
0 Followers
6C1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.98 - €2.51
Previous Close€1.74
Volume0.00
Average Volume (3M)2.63K
Market Cap
€111.70M
Enterprise Value-€39.51M
Total Cash (Recent Filing)$174.51M
Total Debt (Recent Filing)$13.97M
Price to Earnings (P/E)N/A
Beta0.89
Next Earnings
May 09, 2024EPS Estimate
-€0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding67,721,658
10 Day Avg. Volume0
30 Day Avg. Volume2,630
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-2.56
Price to Sales (P/S)1.22
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.39
Enterprise Value/Gross Profit-0.39
Enterprise Value/Ebitda20.57
Forecast
1Y Price Target
€2.87Price Target Upside64.90% Upside
Rating ConsensusHold
Number of Analyst Covering6
CytomX Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial HealthCytomX's financial position appears strong with an operational runway into the second half of 2025.
Financial PerformanceCytomX recorded higher revenues than estimated for both the quarter and the full year.
Pipeline DevelopmentRecent datasets from T-cell engagers in solid tumors have been encouraging, demonstrating efficacy in tumors that have historically been challenging for this class.
Bears Say
Analyst RatingThe Underweight rating on CTMX shares is due to the necessity to see clinical wins from key early stage programs to shift existing negative sentiment.
Drug DevelopmentBristol-Myers Squibb canceled the investigation of a partnered program drug, although other collaborative efforts continue.
EarningsCytomX reported a net profit of $0.01 per share which was below the prior estimate of $0.06 per share.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.35% Other Institutional Investors
99.65% Public Companies and
Individual Investors
6C1 FAQ
What was CytomX Therapeutics Inc’s price range in the past 12 months?
CytomX Therapeutics Inc lowest stock price was €0.98 and its highest was €2.50 in the past 12 months.
What is CytomX Therapeutics Inc’s market cap?
Currently, no data Available
When is CytomX Therapeutics Inc’s upcoming earnings report date?
CytomX Therapeutics Inc’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were CytomX Therapeutics Inc’s earnings last quarter?
CytomX Therapeutics Inc released its earnings results on Mar 11, 2024. The company reported €0.019 earnings per share for the quarter, beating the consensus estimate of -€0.045 by €0.064.
Is CytomX Therapeutics Inc overvalued?
According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued.
Does CytomX Therapeutics Inc pay dividends?
CytomX Therapeutics Inc does not currently pay dividends.
What is CytomX Therapeutics Inc’s EPS estimate?
CytomX Therapeutics Inc’s EPS estimate is -€0.07.
How many shares outstanding does CytomX Therapeutics Inc have?
Currently, no data Available
What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?
CytomX Therapeutics Inc reported an EPS of €0.019 in its last earnings report, beating expectations of -€0.045. Following the earnings report the stock price went down -13.744%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc?
Among the largest hedge funds holding CytomX Therapeutics Inc’s share is Platinum Investment Management. It holds CytomX Therapeutics Inc’s shares valued at N/A.
---
CytomX Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€2.87 (64.90% Upside)
€2.87 (64.90% Upside)
Insider Transactions
Bought Shares
Worth $72.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.43%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
---
6C1 Earnings Call
Q4 2024
0:00 / 0:00
---
6C1 Stock 12 Months Forecast
Average Price Target
€2.87
▲(64.90% Upside)
Technical Analysis
Best Analysts Covering 6C1
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
-9.46%
reiterated a buy rating last month
Copying Peter Lawson's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -9.46% per trade.
---